Pharming Submits Human Recombinant C1 Inhibitor To EMEA
This article was originally published in The Pink Sheet Daily
Executive Summary
The transgenic rabbit-produced biologic could prove controversial.
You may also be interested in...
Lev Pharmaceuticals’ Hereditary Angioedema Therapy Cinryze Could Reach Market In Early 2008
Second-generation C1 inhibitor has “tremendous body of safety and efficacy data” behind it from decades of use in Europe, CEO tells “The Pink Sheet” DAILY.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.